## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Cynthia B. ROBINSON, et al.

Serial Number: 10/698.076

Filing Date: October 29, 2003

Title: COMBINATION OF

DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULLMONARY DISEASE Group Art Unit: 1617

Examiner: Umamaheswari Ramachandran

CONFIRMATION NO: 9185

FILED ELECTRONICALLY ON: August 31, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached form PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.		$\  \  \  \  \  \  \  \  \  \  \  \  \  $				
			(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under $\S1.53(d)$ ;		
				OR		
			(2)	It is being filed within 3 months of entry of the national stage as set forth in $\S 1.491$ in an international application;		
				OR		
			(3)	It is being filed before the mailing of a first Office action on the merits;		
				OR		
			(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under $\S 1.114$ .		
B. \(\simeg 37 CFR \)\(\frac{8}{1.97}(c)\). Although this Information Disclosure Statement is being file specified in 37 CFR \(\frac{8}{1.97}(b)\), above, it is filed before the mailing date of the ear office action under \(\frac{8}{1.113}\), (2) a notice of allowance under \(\frac{8}{1.311}\), or (3) an actic closes prosecution on the merits, this Information Disclosure Statement should be cit is accompanied by one of:				$R(\hat{S}_1, P) T(\hat{b})$ , above, it is filed before the mailing date of the earlier of (1) a final $\hat{S}_1$ 1.113, (2) a notice of allowance under $\hat{S}_1$ 1.311, or (3) an action that otherwise on the merits, this Information Disclosure Statement should be considered because		
			a stater	nent as specified in §1.97(e) provided concurrently herewith;		
				OR		
		$\boxtimes$		f $\$180.00$ as set forth in $\$1.17(p)$ authorized below, enclosed, or included with the nt of other papers filed together with this statement.		
C.	dat	e of the s being	earlier o	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under $\S1.113$ or (2) a notice of allowance under $\S1.311$ , fore payment of the issue fee and should be considered because it is accompanied		
			i. a st	atement as specified in §1.97(e);		
				AND		
				the of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included in the payment of other papers filed together with this Statement.		
D.		37 CFI	R §1.97(	e). Statement.		
			A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);		
				AND/OR		
		П	A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);		
				AND/OR		
			inform the cor	of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on mmunication is provided in lieu of a statement under 37 C.F.R. $\S$ 1.97(e)(1) as 2d for under MPEP 609.04(b) V.		
Ε.	☐ Statement Under 37 C.F.R. §1.704(d). Each item of information contained in the info disclosure statement was first cited in a communication from a foreign patent office in a comapplication that was received by an individual designated in § 1.56(c) not more than thirty (2 prior to the filing of this information disclosure statement. This statement is made pursuar					

- 2 -

		requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term for Applicant(s) delay.			
F.		R §1.98(a)(2). The content of the Information Disclosure Statement is as follows:			
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.			
		OR			
	$\boxtimes$	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.			
		AND/OR			
	$\boxtimes$	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR $\S1.98$ (a)(2).			
		AND/OR			
	$\boxtimes$	Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR $\S1.98(a)(2)(iii)$ .			
G.	37 CF.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or			
		Pursuant to 37 CFR $\S1.98(a)(3)(i)$ , a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.			
		Pursuant to MPEP 609(B), an English language copy of a forciegn search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.			
		OR			
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:			
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.			
H.	☐ 37 CF	R §1.98(d). Copies of patents, publications and pending U.S. patent applications, or other n specified in 37 C.F.R. § 1.98(a) are not provided herewith because:			
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.			
		Application in which the information was submitted:			
		Information Disclosure Statement(s) filed on:			
		AND			
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR $\S1.98$ .			

I. \( \sumes \) Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 30775-714.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: August 28, 2007

Albe

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971